Half Year Trading Update
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.
Optima Health plc
(“Optima”, the “Company”, and, together with its subsidiaries, the “Group”)
Half Year Trading Update
First-half delivery of 60% increase in revenues, reflecting the successful integration of PAM Healthcare and continued growth across the Group
LONDON, UK, 20 October 2026, Optima Health (AIM: OPT), the UK’s leading provider of technology enabled corporate health and wellbeing solutions, today provides a trading update ahead of publication of the Group’s unaudited results for the half year ended 30 September 2026 (“H1 27” or the “Period”).
Highlights
- H1 FY27 revenue expected to be approximately £96 million, c.60% ahead of the prior year period (H1 FY26: £59.5 million), reflecting the acquisition of PAM Healthcare and continued growth across the Group's core operations.
- Trading remains in line with the Board's expectations.
- PAM Healthcare integration progressing to plan, with operational and commercial synergies being realised.
- New business wins in the first half of an annualised £10.6 million (H1 FY26: £1.9 million).
- New contract win secured with HMRC.
- Adjacent market contract secured supporting delivery of the Home Office-procured Support for Victims of Modern Slavery programme.
- Strong pipeline of opportunities across public and private sector markets.
- Robust balance sheet with net debt (excluding leases) of £70.4 million as at 30 September 2026 (£94.4 million at 31 March 2026).
- Remains on track to deliver FY27 results in line with current market expectations
Optima is pleased to report revenue for the first half of FY27 is expected to be approximately 60% ahead of the prior year period at £96 million, reflecting the contribution from the acquisition of PAM Healthcare completed in March 2026, together with continued growth across the Group's occupational health and wellbeing operations.
Trading during the period was in line with the Board's expectations. The integration of PAM Healthcare continues to progress to plan, with operational and commercial synergies being realised across the enlarged Group, and demand across the Group's core markets remaining resilient throughout the period. The Board therefore continues to expect full year FY27 results to be in line with market expectations.
The Group secured a number of contract awards during the period, notably a new programme with HMRC, together with an adjacent market win supporting delivery of the Home Office-procured Support for Victims of Modern Slavery contract. Annualised new business wins equates to £10.6 million.
The Group continues to focus on cash generation and deleveraging following the acquisition of PAM Healthcare in March 2026 and remains well positioned to execute its growth strategy. The Group’s unaudited net debt position (excluding leases) at 30 September 2026 was £70.4 million, comprised of a cash balance of £11.6 million, and £82 million of debt.
Optima expects to report its Interim Results for the six months ended 30 September 2026 by December 2026.
Jonathan Thomas, Chief Executive Officer of Optima Health, said:
“We have delivered a strong first-half performance, with revenue expected to be approximately 60% ahead of the prior year period, reflecting the successful integration of PAM Healthcare and continued growth across the Group.
“We are particularly encouraged by the progress being made across the enlarged business. Integration is advancing well, synergy delivery remains on track and we continue to see demand for our services across both public and private sector markets.
“During the period, we secured a number of important new contract awards, including with HMRC, and our support of the Home Office-procured Support for Victims of Modern Slavery programme. These wins demonstrate the strength of our market position, the breadth of our capabilities and the opportunities available to the Group as we continue to expand into adjacent markets.
We enter the second half of the year with a strong pipeline of opportunities, increasing operational momentum and confidence in the Group's outlook. The Board remains focused on delivering sustainable growth and creating long-term value for all stakeholders.”
Enquiries
|
|
About Optima Health
Optima Health is the UK and Ireland’s leading provider of occupational health and wellbeing services, delivering clinically led, technology-driven solutions to organisations across the public and private sectors. The Group employs more than 1,250 clinicians directly, supported by a wider network of more than 1,000 subcontracted associate clinicians, and delivers more than one million interventions each year across a national network of clinics.
For more information visit www.optimahealth.co.uk or www.optimahealth.ie
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE